Comment from Tomas Aleman

Summary: Dr. Tomas S. Aleman, a professor at the University of Pennsylvania, supports the Haystack Project’s Petition for Rulemaking. He argues that the FDA should adopt a framework that considers disease context when evaluating clinical investigations for rare diseases, specifically to ensure that study designs are fit-for-purpose and reflect clinical realities.